News
Home | News
WuXi AppTec Triples Peptide Manufacturing Capacity and Launches the New Taixing API Manufacturing Site
January 8, 2024Expansion Boosts Solid-Phase Peptide Synthesis Total Reactor Volume to 32,000 Liters in Response to Surging Demand Shanghai, China – January 8, 2024 — WuXi AppTec, a global company that provides a broad…
WuXi STA Debuts Its First High Potency Sterile Injectable Manufacturing Line at Wuxi City Site
July 17, 2023Shanghai, China, July 17, 2023 -- WuXi STA, a global Contract Research, Development, and Manufacturing Organization (CRDMO), today launched its first high potency (HP), fully automated sterile injectable manufacturing line at the…
WuXi STA Forms Strategic Partnership with Ark Biopharmaceutical for the Commercial Supply of Ziresovir
May 23, 2023SHANGHAI, CHINA, May 23, 2023 - WuXi STA, a subsidiary of WuXi AppTec, and Shanghai Ark Biopharmaceutical Co., Ltd. (ArkBio) announced a strategic partnership for the commercial supply of ziresovir, a novel…
WuXi TIDES Adds New Peptide Manufacturing Capacity and Large-Scale Continuous Purification System
April 5, 2023April 5, 2023 - WuXi STA, a global Contract Research, Development, and Manufacturing Organization (CRDMO), today announced that it has added two 2,000 L reactors and a large-scale continuous purification system for…
WuXi STA Receives 2023 CDMO Leadership Award in Recognition of Capabilities and Reliabilities
February 24, 2023WuXi STA, a global leading Contract Research, Development, and Manufacturing Organization (CRDMO), is pleased to share that it has been named a recipient of the 2023 CDMO Leadership Award for the ninth…
WuXi STA Launches First Continuous Manufacturing Line for Oral Solids
January 3, 2023SHANGHAI, CHINA, January 3, 2023 – WuXi STA, a subsidiary of WuXi AppTec, today announced that its first drug product Continuous Manufacturing (CM) line for oral solids is in operation at the…
